Stem cell transplantation for multiple myeloma: Current and future status Journal Article

Author: Giralt, S.
Article Title: Stem cell transplantation for multiple myeloma: Current and future status
Abstract: High-dose melphalan with autologous stem cell support has been an integral part of myeloma therapy for more than 25 years either as salvage therapy or as consolidation of an initial remission. Although multiple phase III trials have demonstrated that this therapy results in higher response rates and longer remission duration than conventional chemotherapy the use of thalidomide, lenalidomide and bortezomib as induction therapy have limited the clinical relevance of these trials. In this manuscript, we will summarize the results of ongoing and recently published clinical trials and describe how they have impacted current transplant recommendations, and their relevance to the treatment of myeloma patients in developing countries. © W. S. Maney & Son Ltd 2012.
Keywords: event free survival; treatment response; overall survival; lenalidomide; prednisone; thalidomide; doxorubicin; placebo; dose response; drug efficacy; drug safety; antineoplastic agents; progression free survival; bortezomib; multiple myeloma; boronic acids; pyrazines; history, 21st century; cyclophosphamide; dexamethasone; melphalan; vincristine; autologous stem cell transplantation; stem cell transplantation; carmustine; cost effectiveness analysis; history, 20th century; patient care; immunomodulation; developing countries; myeloma
Journal Title: Hematology
Volume: 17
Issue: Suppl. 1
ISSN: 1024-5332
Publisher: Maney Publishing  
Date Published: 2012-04-01
Start Page: S117
End Page: S120
Language: English
DOI: 10.1179/102453312x13336169156258
PROVIDER: scopus
PUBMED: 22507797
Notes: --- - "Export Date: 1 May 2012" - "CODEN: HMATF" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Sergio Andres Giralt
    516 Giralt